Straits Times Index
3,227.10 -35.97 (-1.10%) Nikkei
27,153.83 -159.30 (-0.58%) Hang Seng
17,933.27 -214.68 (-1.18%) FTSE 100
7,018.60 -140.92 (-1.97%) BTC-USD
19,019.81 -113.62 (-0.59%) CMC Crypto 200
434.61 -9.92 (-2.23%)
InMode Ltd. (INMD)
After hours:
| Previous close | 28.77 |
| Open | 28.21 |
| Bid | 27.11 x 900 |
| Ask | 28.00 x 1300 |
| Day's range | 26.83 - 28.33 |
| 52-week range | 20.60 - 99.27 |
| Volume | |
| Avg. volume | 1,718,042 |
| Market cap | 2.286B |
| Beta (5Y monthly) | 2.31 |
| PE ratio (TTM) | 15.29 |
| EPS (TTM) | 1.80 |
| Earnings date | 24 Oct 2022 - 28 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.00 |
- Motley Fool
3 Highly Profitable Stocks That Are Super Cheap Right Now
Bear markets are never fun. Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities. Cosmetic surgery company InMode (NASDAQ: INMD), Swiss pharma giant Novartis (NYSE: NVS), and diabetes care behemoth DexCom (NASDAQ: DXCM) are three highly profitable companies that have been unfairly punished by this irrational market.
- Motley Fool
Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?
The popularity of cosmetic procedures is unquestionably on the rise. Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. At the same time, healthcare equipment provider InMode (NASDAQ: INMD) has been punished by Wall Street's current skepticism about growth stocks.
- Motley Fool
This Beaten-Down Growth Stock Has Significant Upside Potential. Time to Buy?
Shareholders of medical technology company InMode (NASDAQ: INMD) have not had a great 2022; the stock has fallen roughly 50% since the beginning of the year. Here are three reasons to consider InMode as a long-term growth stock for your portfolio. InMode designs and builds non-invasive medical equipment for cosmetic procedures like face and body contouring, hair removal, and women's wellness.
